Story perspectives

Breakthrough Drug Targets RAS Mutations in Melanoma

11/5/2025

35 6

Summary

Story summary

Researchers at Moffitt Cancer Center advance NRAS-mutant melanoma treatment with daraxonrasib, a RAS inhibitor.
Daraxonrasib directly targets active RAS proteins and blocks pathways essential for tumor growth.
Early-phase trials show a complete response in one patient and a substantial partial response in another.
The therapy increases T cell infiltration and boosts the immune response against tumors.
Its potential extends to other RAS-driven cancers, and ongoing trials will assess efficacy and safety.

1 of 1

Story summary

Researchers at Moffitt Cancer Center advance NRAS-mutant melanoma treatment with daraxonrasib, a RAS inhibitor.
Daraxonrasib directly targets active RAS proteins and blocks pathways essential for tumor growth.
Early-phase trials show a complete response in one patient and a substantial partial response in another.
The therapy increases T cell infiltration and boosts the immune response against tumors.
Its potential extends to other RAS-driven cancers, and ongoing trials will assess efficacy and safety.